Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is becoming increasingly fragmented as more biomarker-driven therapies enter the market. Nevertheless, owing to the limited size of these patient subpopulations, the immune checkpoint inhibitors, most notably Keytruda (Merck & Co.), continue to dominate the NSCLC market. Competition is set to intensify further over the forecast period as multiple immune checkpoint inhibitor-based combination therapies gain approval and enter clinical practice. In addition, a flurry of novel agents and regimens from different drug classes are in development for NSCLC, including ALK, MET, and RET inhibitors, immune checkpoint inhibitors, angiogenesis inhibitors, and therapeutic vaccines, all vying for a share of the increasingly crowded and competitive market.
- How are the drug-treatable populations defined in NSCLC? How do these differ in size, and will drug-treatment rates per population change over time?
- How will recent and expected market approvals shape the treatment landscape in first-line metastatic NSCLC? Which agents and combinations will dominate this commercially lucrative setting?
- What pipeline products are considered most promising, and what uptake and patient share could they secure in NSCLC? What key therapies are in earlier phases of development?
- What are the key market drivers and constraints in NSCLC, and how will the market evolve over the forecast period?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 16 interviews with experts and country-specific surveys with medical oncologists (~30 per country) who treat NSCLC.
Epidemiology: Diagnosed and recurrent incidence of adenocarcinoma, squamous cell carcinoma, large cell carcinoma and other, and unverified NSCLC.
Population segments in market forecast: Stage IB/II, stage III, first-line, second-line, and third-line for metastatic adenocarcinoma, squamous cell carcinoma, large cell carcinoma and other, and unverified NSCLC.
Emerging therapies: Phase III/PR: 27 drugs; coverage of select agents in Phase II and Phase I development.
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.